Network Pharmacology Combined with Functional Metabolomics Discover Bile Acid Metabolism As a Promising Target for Mirabilite Against Colorectal Cancer

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 13

PMID 35546810

Authors

Hui Sun

Hong-Lian Zhang

Ai-Hua Zhang

Xiao-Hang Zhou

Xiang-Qian Wang

Ying Han

Guang-Li Yan

Liang Liu

Xi-Jun Wang

Affiliations

Soon will be listed here.

Abstract

In this study, a combination of network pharmacology and metabolomics was used to explore the mechanism by which mirabilite regulates bile acid metabolism in the treatment of colorectal cancer. The PharmMapper web server was applied to make preliminary predictions for the treatment targets of mirabilite and to predict the interaction between mirabilite and disease targets using Discovery Studio 2.5. Furthermore, the urine metabolic profile was analyzed by the UPLC-Q-TOF-MS technology. The original data were processed by Progenesis QI software and analyzed by multivariate pattern recognition, which allowed us to reveal the metabolic disturbance in colorectal cancer and explain the therapeutic effect of mirabilite. The network pharmacology results showed that mirabilite can act on the disease targets, and the sites of action include amino acid residues Arg-364 and Asp-533, as well as nucleotides TPC-11, DG-112 and DA-113. Based on metabolomics, potential biomarkers were found to lie in the relevant pathways of bile acid metabolism, such as taurine, chenodeoxycholic acid, cholic acid, and deoxycholic acid. The results showed that mirabilite could regulate the distribution of overall metabolic disturbance, and bile acid metabolism was the main targeted pathway. Additionally, we predicted the upstream targets by ingenuity pathway analysis and found that mirabilite played a significant role in regulating the bile acid-related biomarkers, which allowed comprehensive analysis of the effect of mirabilite on colorectal cancer. This study fully explained the role of mirabilite in inhibiting colorectal cancer, which mainly occurs through bile acid metabolism, the approach of network pharmacology combined with functional metabolomics.

Citing Articles

Metabolomics combined with network pharmacology reveals anti-asthmatic effects of on allergic asthma rats.

Abulaiti K, Aikepa M, Ainaidu M, Wang J, Yizibula M, Aikemu M Chin Herb Med. 2024; 16(4):599-611.

PMID: 39606263 PMC: 11589474. DOI: 10.1016/j.chmed.2024.02.001.

Mineral crude drug mirabilite (Mangxiao) inhibits the occurrence of colorectal cancer by regulating the -bile acid-intestinal farnesoid X receptor axis based on multiomics integration analysis.

Zhou X, Sun H, Ren J, Yan G, Yang L, Zhang H MedComm (2020). 2024; 5(5):e556.

PMID: 38665997 PMC: 11043829. DOI: 10.1002/mco2.556.

The application of mirabilite in traditional Chinese medicine and its chemical constituents, processing methods, pharmacology, toxicology and clinical research.

Tao L, Fu J, Wang F, Song Y, Li Y, Zhang J Front Pharmacol. 2024; 14:1293097.

PMID: 38239194 PMC: 10794775. DOI: 10.3389/fphar.2023.1293097.

[Integrated analysis of serum untargeted metabolomics and targeted bile acid metabolomics for identification of diagnostic biomarkers for colorectal cancer].

Wang X, Zhu Y, Zhou H, Huang Z, Chen H, Zhang J Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(3):443-453.

PMID: 37087590 PMC: 10122735. DOI: 10.12122/j.issn.1673-4254.2023.03.15.

Extensive identification of serum metabolites related to microbes in different gut locations and evaluating their associations with porcine fatness.

Liu Q, He M, Zeng Z, Huang X, Fang S, Zhao Y Microb Biotechnol. 2023; 16(6):1293-1311.

PMID: 36916818 PMC: 10221527. DOI: 10.1111/1751-7915.14245.

References

Arakawa Y, Ozaki K, Okawa Y, Yamada H . Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines. Oncol Rep. 2013; 30(3):1053-8. PMC: 3783056. DOI: 10.3892/or.2013.2594. View

Wang X, Zhang A, Yan G, Sun W, Han Y, Sun H . Metabolomics and proteomics annotate therapeutic properties of geniposide: targeting and regulating multiple perturbed pathways. PLoS One. 2013; 8(8):e71403. PMC: 3744542. DOI: 10.1371/journal.pone.0071403. View

Johnson C, Ivanisevic J, Siuzdak G . Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016; 17(7):451-9. PMC: 5729912. DOI: 10.1038/nrm.2016.25. View

Molinaro A, Wahlstrom A, Marschall H . Role of Bile Acids in Metabolic Control. Trends Endocrinol Metab. 2017; 29(1):31-41. DOI: 10.1016/j.tem.2017.11.002. View

Zhang A, Sun H, Han Y, Yan G, Wang X . Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS One. 2013; 8(5):e64381. PMC: 3655955. DOI: 10.1371/journal.pone.0064381. View

Zhang A, Yu J, Sun H, Kong L, Wang X, Zhang Q . Identifying quality-markers from Shengmai San protects against transgenic mouse model of Alzheimer's disease using chinmedomics approach. Phytomedicine. 2018; 45:84-92. DOI: 10.1016/j.phymed.2018.04.004. View

Yun J, Mullarky E, Lu C, Bosch K, Kavalier A, Rivera K . Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015; 350(6266):1391-6. PMC: 4778961. DOI: 10.1126/science.aaa5004. View

Ocvirk S, OKeefe S . Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions. Curr Nutr Rep. 2018; 6(4):315-322. PMC: 5802424. DOI: 10.1007/s13668-017-0219-5. View

Louis P, Hold G, Flint H . The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12(10):661-72. DOI: 10.1038/nrmicro3344. View

10.

Wahlstrom A, Sayin S, Marschall H, Backhed F . Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016; 24(1):41-50. DOI: 10.1016/j.cmet.2016.05.005. View

11.

Ajouz H, Mukherji D, Shamseddine A . Secondary bile acids: an underrecognized cause of colon cancer. World J Surg Oncol. 2014; 12:164. PMC: 4041630. DOI: 10.1186/1477-7819-12-164. View

12.

Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur P, Cazanave S . The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2017; 67(2):534-548. PMC: 5764808. DOI: 10.1002/hep.29359. View

13.

Calmus Y, Poupon R . Shaping macrophages function and innate immunity by bile acids: mechanisms and implication in cholestatic liver diseases. Clin Res Hepatol Gastroenterol. 2014; 38(5):550-6. DOI: 10.1016/j.clinre.2014.07.007. View

14.

Zhang A, Sun H, Qiu S, Wang X . NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn Reson Chem. 2013; 51(9):549-56. DOI: 10.1002/mrc.3985. View

15.

Zhou X, Cao L, Jiang C, Xie Y, Cheng X, Krausz K . PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun. 2014; 5:4573. PMC: 4164778. DOI: 10.1038/ncomms5573. View

16.

Choi C, Ignjatovic-Wilson A, Askari A, Lee G, Warusavitarne J, Moorghen M . Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015; 110(10):1461-71. PMC: 4697133. DOI: 10.1038/ajg.2015.248. View

17.

Qiu S, Zhang A, Zhang T, Sun H, Guan Y, Yan G . Dissect new mechanistic insights for geniposide efficacy on the hepatoprotection using multiomics approach. Oncotarget. 2018; 8(65):108760-108770. PMC: 5752478. DOI: 10.18632/oncotarget.21897. View

18.

Adami H, Bretthauer M, Emilsson L, Hernan M, Kalager M, Ludvigsson J . The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016; 65(6):889-93. PMC: 5226357. DOI: 10.1136/gutjnl-2015-311003. View

19.

Ikegami T, Matsuzaki Y . Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res. 2007; 38(2):123-31. DOI: 10.1111/j.1872-034X.2007.00297.x. View

20.

Wang Y, Zhang X, Li C . Applying Hot Compresses with Rhubarb and Mirabilite to Reduce Pancreatic Leakage Occurrence in the Treatment of Severe Acute Pancreatitis. Iran J Public Health. 2017; 46(1):136-138. PMC: 5401925. View